Advanced Search

Most Popular

Comparison of 22C3 PharmDx and SP263 Assays to Test PD-L1 Expression in NSCLC

Positive Data of APR-246 & Azacitidine in Patients with TP53 MDS & AML

The Effect of Systemic Chemotherapy on Survival in Patients With Localized, Regional, or Metastatic Adenocarcinoma of the Urinary Bladder

Poll of the Week

A patient is seeing you in follow- up for his mCPRC including metastasis to the lungs, liver, and spine. The patient asks about changing to enzalutamide but is also open to other therapies. Which of the following should you tell him?